Phase II study of cetuximab plus concomitant boost radiotherapy in Japanese patients with locally advanced squamous cell carcinoma of the head and neck

Japanese Journal of Clinical Oncology

Volumn 43, Issue 5, 2013, Pages 476-482

  Okano, Susumu ^a,b   Yoshino, Takayuki ^a   Fujii, Masato ^c   Onozawa, Yusuke ^d   Kodaira, Takeshi ^e   Fujii, Hirofumi ^f   Akimoto, Tetsuo ^a   Ishikura, Satoshi ^g   Oguchi, Masahiko ^h   Zenda, Sadamoto ^a,i   de Blas, Barbara ^j   Tahara, Makoto ^a  

^a NATIONAL CANCER CENTER HOSPITAL EAST   (Japan)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

^d SHIZUOKA CANCER CENTER   (Japan)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

^f JICHI MEDICAL UNIVERSITY   (Japan)

^g JUNTENDO UNIVERSITY   (Japan)

^h CANCER INSTITUTE HOSPITAL   (Japan)

ⁱ TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^j MERCK KGAA   (Germany)

more..

Author keywords

Cetuximab; Concomitant boost; Japanese; Locally advanced; Radiotherapy; Squamous cell carcinoma of the head and neck

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR;

ACNE; ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL ARTICLE; CONSTIPATION; DERMATITIS; DRY SKIN; DYSGEUSIA; FEMALE; FEVER; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; JAPANESE; MALE; MUCOSA INFLAMMATION; PHASE 2 CLINICAL TRIAL; RADIATION INJURY; SKIN INJURY; SKIN MANIFESTATION; STOMATITIS; XEROSTOMIA;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, SQUAMOUS CELL; CHEMORADIOTHERAPY; DOSE FRACTIONATION; DRUG ADMINISTRATION SCHEDULE; FEASIBILITY STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; JAPAN; MALE; MIDDLE AGED; MUTATION; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84877322780     PISSN: 03682811     EISSN: 14653621     Source Type: Journal    
DOI: 10.1093/jjco/hyt030     Document Type: Article

References (19)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-917.
2. Japanese Society of Medical Oncology. Clinical Oncology Update-Essentials for the Medical Oncologist. 2nd edn. Tokyo, Japan: Nankodo 2009.
3. Budach V, Bernier J, Lefebvre J-L, et al. Trends in the treatment of locally advanced squamous cell carcinoma of the head and neck (LASCCHN) in Europe between 2006 and 2009. Ann Oncol 2010;21 (Suppl 8):viii321-2. Updated information presented at meeting.
4. Wong SJ, Harari PM, Garden AS, et al. Longitudinal Oncology Registry of Head and Neck Carcinoma (LORHAN): analysis of chemoradiation treatment approaches in the United States. Cancer 2011;117:1679-86.
5. Christensen ME, Therkildsen MH, Hansen BL, Albeck H, Hansen GN, Bretlau P. Epidermal growth factor receptor expression on oral mucosa dysplastic epithelia and squamous cell carcinomas. Eur Arch Otorhinolaryngol 1992;249:243-7.
6. Rubin Grandis J, Melhem MF, Barnes EL, Tweardy DJ. Quantitative immunohistochemical analysis of transforming growth factor-alpha and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer 1996;78:1284-92.
7. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000;6:2166-74.
8. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
9. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21-8.
10. Zenda S, Onozawa Y, Tahara M, et al. Feasibility study of single agent Cisplatin and concurrent radiotherapy in Japanese patients with squamous cell carcinoma of the head and neck: preliminary results. Jpn J Clin Oncol 2007;37:725-9.
11. Fu KK, Pajak TF, Trotti A, et al. A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 2000;48:7-16.
12. Ghoshal S, Goda JS, Mallick I, Kehwar TS, Sharma SC. Concomitant boost radiotherapy compared with conventional radiotherapy in squamous cell carcinoma of the head and neck-a phase III trial from a single institution in India. Clin Oncol (R Coll Radiol) 2008;20:212-20.
13. Rathcke IO, Gottschlich S, Gorogh T, Lippert BM, Werner JA. [Incidence of point mutations in Ki-ras codon 12 and 13 in squamous epithelial carcinomas of the head-neck region]. Laryngorhinootologie 1996;75:465-70.
14. Weber A, Langhanki L, Sommerer F, Markwarth A, Wittekind C, Tannapfel A. Mutations of the BRAF gene in squamous cell carcinoma of the head and neck. Oncogene 2003;22:4757-9.
15. Sheikh Ali MA, Gunduz M, Nagatsuka H, et al. Expression and mutation analysis of epidermal growth factor receptor in head and neck squamous cell carcinoma. Cancer Sci 2008;99:1589-94.
16. Gregoire V, Lefebvre JL, Licitra L, Felip E. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(Suppl 5):v184-6.
17. Pfister DG, Ang KK, Brizel DM, et al. National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology. Head and neck cancers. J Natl Compr Canc Netw 2011;9:596-650.
18. Japan Society of Clinical Oncology. Clinical Practice Guidelines. http://jsco-cpg.jp/guideline/15_siryou.html (7 February 2012, date last accessed).
19. Levy AR, Johnston KM, Sambrook J, et al. Indirect comparison of the efficacy of cetuximab and cisplatin in squamous cell carcinoma of the head and neck. Curr Med Res Opin 2011;27:2253-9.